Skip to content

Revascularization StrategIes for ST Elevation Myocardial Infarction Trial

Revascularization StrategIes for ST Elevation Myocardial Infarction Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03263468
Acronym
ASSIST-MI
Enrollment
3520
Registered
2017-08-28
Start date
2017-09-01
Completion date
2021-12-31
Last updated
2017-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Stenting, Primary Angioplasty, ST Elevation Myocardial Infarction

Brief summary

This study is being conducted in patients with a major heart attack caused by a blocked artery undergoing Percutaneous Coronary Intervention (PCI) to open up the blockage. Up to 50% of people with an heart attack are found to have one or more additional narrowings that did not cause the heart attack. At present the best way to manage these additional blockages is not known. Many cardiologist recommend opening these blockages at at a later time after the heart attack. The present study is examining if PCI of all blockages at the same time as the PCI for the artery that caused the major heart attack (SS-PCI) will reduce the amount of heart damage compared to performing PCI of additional blockages 2-45 days later (IRA-PCI). Clinical follow up will be completed at 3, 12 and 24 months to determine heart function and monitor adverse events.

Interventions

PROCEDURESame sitting PCI with complete revascularization

revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting at the time of primary PCI

PROCEDUREStaged PCI with complete revsacularization >48 hours pf primary PCI

revascualrization of the non IRA (infarct related artery) of \> 2.0 mm by coronary angioplasty/stenting \>48 hours to 45 days post primary PCI

Sponsors

Unity Health Toronto
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* ST elevation myocardial infarction evidenced by new ST elevation at the J point in at least 2 contiguous leads of ≥ 2 mm (0.2mV) in men or ≥ 1.5mm (0.15mV) in women in leads V2-V3 and/or ≥ 1mm (0.1mV) in other contiguous chest leads or limb leads. * MVD as evidenced by \> one significant (\>70% by visual assessment or FFR \< 0.80 for 50-70% stenosis) stenosis in the non-IRA \>2mm in diameter. * Successful IRA-PCI with \<30% residual angiographic stenosis and TIMI III flow * Written informed consent

Exclusion criteria

* Age ≤ 18 years * Prior coronary artery bypass graft (CABG) surgery * Administration of thrombolytic therapy. * Hemodynamic instability as evidenced by SBP\<90 mmHg, Killip class ≥3, and/or need for inotropes/vasopressors. * Known renal insufficiency (estimated GFR \< 30 ml/min/1.73m2) * Non-IRA stenosis is a chronic total occlusion (CTO) * Plan by treating physician to treat non-IRA stenosis with coronary artery bypass surgery

Design outcomes

Primary

MeasureTime frameDescription
Major adverse clinical events90 daysComposite of all-cause mortality, myocardial infarction, heart failure and unplanned revascularization

Secondary

MeasureTime frame
Stroke90 days
Contrast nephropathy90 days
Major vascular complication90 days
EQ-5D quality of life assessment90 days
Major bleeding90 days
Myocardial infarction90 days
Heart failure90 days
All cause mortality90 days
Unplanned revascularization90 days
Incremental Cost-Effectiveness Ratio (ICER)90 days

Contacts

Primary ContactVal Panzov
panzovv@smh.ca416-864-6060

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026